Insider · CIK 0001718725
Ramy A Mahmoud
Files at OPTN (OptiNose, Inc.). First filing Dec 20, 2023, latest Dec 18, 2024.
In brief
Ramy A Mahmoud files SEC Form 4 as CEO and director at OPTN (OptiNose, Inc.). Since Dec 20, 2023, Ramy A Mahmoud has reported 0 open-market buys worth $0 and 2 open-market sells worth $15k, the latest filed on Dec 18, 2024.
A track record needs three past buys with six months of prices behind them; Ramy A Mahmoud has 0, so none is measured yet.
The newest scored trade: sold $2,030 of OPTN on Dec 17, 2024, filed Dec 18, 2024, scored 33 (weak).
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | OptiNose, Inc. | $2,030 4,614 shares | -0% | - | |
| 33Weak | OptiNose, Inc. | $13k 11,114 shares | -2% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 14, 2025 | OPTN Optinose, Inc. | 363 0.00% of outstanding | $1,949 | Mar 17, 2025 | $36k |
| Feb 28, 2025 | OPTN Optinose, Inc. | 6,250 0.06% of outstanding | $36k | Mar 3, 2025 | $2,030 |
| Dec 17, 2024 | OPTN Optinose, Inc. | 4,997 0.00% of outstanding | $2,249 | Dec 17, 2024 | $4,246 |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Common Stock | -303,176 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Common Stockindirect: By: The Ramy Mahmoud 2014 Trust for Cynthia Mahmoud | -11,494 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,750 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -26,532 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -36,613 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,414 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -10,000 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,020 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,541 | - | - | 0 | May 21, 2025 |
| May 21, 2025 | OPTN OptiNose, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,476 | - | - | 0 | May 21, 2025 |
| Dec 17, 2024 | OPTN OptiNose, Inc. | SOpen-market sale Common Stock | -4,614 | $0.44 | $2,030 | 1,197,483 | Dec 18, 2024 |
| Dec 15, 2023 | OPTN OptiNose, Inc. | AGrant or award Common Stock | +6,113 | $0.00 | $0 | 520,842 | Dec 20, 2023 |
| Dec 18, 2023 | OPTN OptiNose, Inc. | SOpen-market sale Common Stock | -11,114 | $1.15 | $13k | 509,728 | Dec 20, 2023 |
Questions about Ramy A Mahmoud
Answered from the filings on this page, as of the latest one.
Is Ramy A Mahmoud buying or selling?
Not in the last 12 months. Ramy A Mahmoud's latest open-market trade on SEC Form 4 was sold $2,030 of OPTN on Dec 17, 2024.
How did Ramy A Mahmoud's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ramy A Mahmoud has 0.
Where does Ramy A Mahmoud file Form 4?
Ramy A Mahmoud has filed Form 4 at OPTN (OptiNose, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.